Clinical Trial Update: Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib given before surgery in patients with stage I-IIIA EGFR-mutant non-small cell lung cancer. Results have been posted on 2024…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-18